RFX8, a member of the Regulatory Factor X (RFX) family, is a transcription factor. The RFX family regulates target genes via the X-box DNA sequence motif, playing roles in cellular specialization and terminal differentiation [3].

In the context of cancer, RFX8 has been implicated in multiple malignancies. In hepatocellular carcinoma (HCC), RFX8 acts as a DDX24 promoter-binding protein, transcriptionally upregulating DDX24 expression, and the RFX8/DDX24/LAMB1 axis promotes HCC progression [1]. In a pan-cancer investigation, RFX8 was found to be most upregulated in LAML among different cancers. Its expression was correlated with various tumor stages, microsatellite instability, tumor mutation burden, immune cell infiltration, and immune-checkpoint expression, and it regulated tumorigenesis and sensitivity to chelerythrine in acute myeloid leukemia (AML) [2]. In stage IV colorectal cancer patients with liver metastasis, RFX8 transcription was an independent risk factor for progression-free survival, and a prediction model including RFX8 was established for prognosis [4]. In thymoma, RFX8 was part of an 11-genes signature prognostic model based on the immune microenvironment [5].

In summary, RFX8 is a transcription factor that appears to play important roles in cancer progression and prognosis across multiple cancer types. Studies in these cancer models have revealed its significance in disease-related biological processes, highlighting its potential as a therapeutic target or prognostic biomarker.